NCT01628042View on ClinicalTrials.gov

A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 16, 2012

Primary Completion Date

January 25, 2013

Study Completion Date

January 25, 2013

Conditions
Overactive Bladder
Interventions
DRUG

Vibegron 100 mg

Vibegron tablets, orally, on Day 1

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01628042 - A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) | Biotech Hunter | Biotech Hunter